Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Read More: Jim Cramer Says He Can't Recommend This Major Automaker, Ceva Is 'Way Too High'During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市場動盪和不確定的時期，許多投資者會轉向股息收益股，這些通常是具有較高的自由現金流並以高紅利派息獎勵股東的公司。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Benzinga的讀者可以通過訪問分析師股票評級頁面，查看他們最喜歡的股票的最新分析師觀點。交易員可以瀏覽Benzinga龐大的分析師評級數據庫，包括按照分析師準確度排序。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是醫療保健板塊三隻高收益股票最準確的分析師評級。
Royalty Pharma plc (NASDAQ:RPRX)
羅伊爾蒂製藥股份有限公司（NASDAQ：RPRX）
- Dividend Yield: 3.05%
- Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.
- Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.
- Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.
- Benzinga Pro's real-time newsfeed alerted to latest RPRX news.
- 股息率：3.05%
- 花旗集團分析師Andrew Baum維持買入評級，並將價格目標從60萬億美元降至40美元。這位分析師的準確率爲72%。
- 摩根士丹利分析師Terence Flynn維持增持評級，並將價格目標從48美元上調至51美元，日期爲7月11日。這位分析師的準確率爲69%。
- 近期資訊：11月4日，Royalty Pharma和syndax pharmaceuticals達成了一項值35000萬美元的版稅資金協議，用於Niktimvo。
- Benzinga Pro的實時新聞提醒了最新的RPRX資訊。
Johnson & Johnson (NYSE:JNJ)
強生公司（紐交所股票代碼：JNJ）
- Dividend Yield: 3.13%
- Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.
- Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.
- Recent News: On Oct. 28, Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.
- Benzinga Pro's real-time newsfeed alerted to latest JNJ news.
- 股息收益率：3.13％
- 花旗集團分析師Joanne Wuensch維持買入評級，並將價格目標從180萬億美元提高至185美元於10月16日。該分析師的準確率爲77%。
- 韋爾斯·法戈分析師Larry Biegelsen維持持平評級，並將價格目標從163萬億美元提高至166美元於10月16日。該分析師的準確率爲72%。
- 近期資訊：約翰遜&約翰遜於10月28日宣佈了Tremfya（guselkumab）用於克羅恩病的3期GRAVITI研究結果。
- Benzinga Pro的實時新聞提醒了最新的JNJ資訊。
Medtronic plc (NYSE:MDT)
美敦力（MDT）公司（紐交所MDT）
- Dividend Yield: 3.12%
- Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.
- Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.
- Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.
- Benzinga Pro's charting tool helped identify the trend in MDT stock.
- 股息收益率：3.12%
- Truist Securities 分析師 Richard Newitter 持有評級，於10月14日將價格目標從90萬億美元提高至93美元。該分析師的準確率爲74%。
- 花旗集團分析師Joanne Wuensch維持中立評級，在10月1日將價格目標從85萬億美元提高至92美元。該分析師的準確率爲77%。
- 近期資訊：美敦力將於2025財年第二季度的11月19日星期二發佈財務業績。
- Benzinga Pro的圖表工具幫助識別了MDt股票的趨勢。
Read More: Jim Cramer Says He Can't Recommend This Major Automaker, Ceva Is 'Way Too High'
閱讀更多：吉姆·克雷默表示他無法推薦這家主要汽車製造商，Ceva的股價「太高了」。
譯文內容由第三人軟體翻譯。
